Novartis/$NVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Ticker
$NVS
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Basel, Switzerland
Employees
75,883
ISIN
US66987V1098
Website
Novartis Metrics
BasicAdvanced
$230B
18.34
$6.38
0.53
$2.60
2.22%
Price and volume
Market cap
$230B
Beta
0.53
52-week high
$120.06
52-week low
$96.06
Average daily volume
1.8M
Dividend rate
$2.60
Financial strength
Current ratio
0.794
Quick ratio
0.502
Long term debt to equity
60.405
Total debt to equity
81.322
Dividend payout ratio (TTM)
60.27%
Interest coverage (TTM)
16.83%
Management effectiveness
Return on assets (TTM)
11.42%
Return on equity (TTM)
32.89%
Valuation
Price to earnings (TTM)
18.339
Price to revenue (TTM)
4.393
Price to book
4.9
Price to tangible book (TTM)
-13.37
Price to free cash flow (TTM)
15.663
Dividend yield (TTM)
2.22%
Forward dividend yield
2.22%
Growth
Revenue change (TTM)
11.50%
Earnings per share change (TTM)
-13.29%
3-year revenue growth (CAGR)
0.14%
3-year earnings per share growth (CAGR)
-15.93%
3-year dividend per share growth (CAGR)
4.34%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Novartis News
AllArticlesVideos
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Reuters·4 days ago
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
WSJ·4 days ago
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
GlobeNewsWire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $230B as of June 06, 2025.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 18.34 as of June 06, 2025.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of June 06, 2025, the dividend rate is $2.59609 and the yield is 2.22%. Novartis has a payout ratio of 60.27% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment date is unconfirmed.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.